E
Elias Abdo Filho
Researcher at University of São Paulo
Publications - 13
Citations - 1554
Elias Abdo Filho is an academic researcher from University of São Paulo. The author has contributed to research in topics: Cervical cancer & Carboplatin. The author has an hindex of 6, co-authored 11 publications receiving 1027 citations.
Papers
More filters
Journal ArticleDOI
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine,Jonathan A. Ledermann,Frédéric Selle,Val Gebski,Richard T Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Andres Poveda,Sandro Pignata,Michael Friedlander,Nicoletta Colombo,Philipp Harter,Keiichi Fujiwara,Isabelle Ray-Coquard,Susana Banerjee,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Patricia Pautier,Tomasz Byrski,Giovanni Scambia,Maria Ornella Nicoletto,Fiona Nussey,Andrew R Clamp,Richard T. Penson,Amit M. Oza,Andrés Poveda Velasco,Manuel Rodrigues,Jean-Pierre Lotz,Diane Provencher,Aleix Prat Aparicio,Laura Vidal Boixader,Clare L. Scott,Kenji Tamura,Mayu Yunokawa,Alla Lisyanskaya,Jacques Medioni,Nicolas Pécuchet,Coraline Dubot,Thibault De La Motte Rouge,Marie-Christine Kaminsky,Béatrice Weber,Alain Lortholary,Christine Parkinson,Jonathan A. Ledermann,Sarah Williams,Jonathan Cosin,James Hoffman,Marie Plante,Allan Covens,Gabe S. Sonke,Florence Joly,Anne Floquet,H. Hirte,Amnon Amit,Tjoung-Won Park-Simon,Koji Matsumoto,Sergei Tjulandin,Jae Hoon Kim,Jae Hoon Kim,Laurence Gladieff,Roberto Sabbatini,David M. O'Malley,Patrick Timmins,Daniel Kredentser,Nuria Laínez Milagro,Maria Pilar Barretina Ginesta,Ariadna Tibau Martorell,Alfonso Gómez de Liaño Lista,Belén Ojeda González,Linda Mileshkin,Masaki Mandai,Ingrid A. Boere,Petronella B. Ottevanger,Joo-Hyun Nam,Elias Abdo Filho,Salima Hamizi,Francesco Cognetti,David Warshal,Elizabeth Dickson-Michelson,Scott Kamelle,Nathalie McKenzie,Gustavo C. Rodriguez,Deborah K. Armstrong,Eva Chalas,Paul Celano,Kian Behbakht,Susan E Davidson,Stephen Welch,Limor Helpman,Ami Fishman,Ilan Bruchim,Magdalena Sikorska,Anna Słowińska,Wojciech Rogowski,Mariusz Bidziński,Beata Śpiewankiewicz,Antonio Casado Herraez,César Mendiola Fernández,Martina Gropp-Meier,Toshiaki Saito,Kazuhiro Takehara,Takayuki Enomoto,Hidemichi Watari,Chel Hun Choi,Byoung-Gie Kim,Jae Weon Kim,Jae Weon Kim,Roberto Hegg,Ignace Vergote +110 more
TL;DR: Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.
Journal ArticleDOI
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Andres Poveda,Anne Floquet,Jonathan A. Ledermann,Rebecca Asher,Richard T. Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Sandro Pignata,Michael Friedlander,Alessandra Baldoni,Tjoung-Won Park-Simon,Gabe S. Sonke,Alla Sergeevna Lisyanskaya,Jae Hoon Kim,Elias Abdo Filho,Ignace Vergote,Phil Rowe,Eric Pujade-Lauraine +18 more
TL;DR: maintenance therapy with the PARP inhibitor olaparib in pts with platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation ...
Journal ArticleDOI
Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
Vanessa da Costa Miranda,Ângelo Bezerra de Souza Fêde,Carlos Henrique dos Anjos,Juliana Ribeiro da Silva,Fernando Barbosa Sanchez,Lyvia Rodrigues da Silva Bessa,Jesus Paula Carvalho,Elias Abdo Filho,Daniela Reis Joaquim de Freitas,Maria Del Pilar Estevez Diz +9 more
TL;DR: Six cycles of neoadjuvant carboplatin and paclitaxel was safe and effective and did not increase perioperative or postoperative complications in patients with stage IIIC/IV disease who were unsuitable for optimal PDS.
Journal ArticleDOI
Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.
Samantha Cabral Severino da Costa,Renata Colombo Bonadio,F. Gabrielli,Andrea Aranha,Maria Luiza Nogueira Dias Genta,Vanessa C. Miranda,Daniela Reis Joaquim de Freitas,Elias Abdo Filho,Patrícia Alves Ferreira,Karime Kalil Machado,Mariana Scaranti,Heloisa de Andrade Carvalho,Maria Del Pilar Estevez-Diz +12 more
TL;DR: This study shows that the addition of NAC consisting of cisplatin and gemcitabine to standard CRT is not superior and is possibly inferior to CRT alone for the treatment of LACC.
Journal ArticleDOI
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
Andres Poveda,Anne Floquet,Jonathan A. Ledermann,Rebecca Asher,Richard T. Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Sandro Pignata,Michael Friedlander,Alessandra Baldoni,Tjoung-Won Park-Simon,Kenji Tamura,Gabe S. Sonke,Alla Lisyanskaya,Jae Hoon Kim,Elias Abdo Filho,Tsveta Milenkova,Elizabeth S. Lowe,Phil Rowe,Ignace Vergote,Eric Pujade-Lauraine,ENGOT-Ov Investigators +22 more